Ionis Pharmaceuticals Debt

IONS Stock  USD 35.73  0.17  0.47%   
Ionis Pharmaceuticals holds a debt-to-equity ratio of 2.005. At this time, Ionis Pharmaceuticals' Short and Long Term Debt Total is comparatively stable compared to the past year. Net Debt is likely to gain to about 1.1 B in 2024, despite the fact that Net Debt To EBITDA is likely to grow to (4.35). . Ionis Pharmaceuticals' financial risk is the risk to Ionis Pharmaceuticals stockholders that is caused by an increase in debt.

Asset vs Debt

Equity vs Debt

Ionis Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Ionis Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Ionis Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Ionis Pharmaceuticals' stakeholders.
For most companies, including Ionis Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Ionis Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Ionis Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
8.5161
Book Value
4.198
Operating Margin
(1.11)
Profit Margin
(0.45)
Return On Assets
(0.07)
At this time, Ionis Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.1 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 261.3 M in 2024.
  
Check out the analysis of Ionis Pharmaceuticals Fundamentals Over Time.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

Ionis Pharmaceuticals Bond Ratings

Ionis Pharmaceuticals financial ratings play a critical role in determining how much Ionis Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Ionis Pharmaceuticals' borrowing costs.
Piotroski F Score
3
FrailView
Beneish M Score
(2.47)
Unlikely ManipulatorView

Ionis Pharmaceuticals Debt to Cash Allocation

Many companies such as Ionis Pharmaceuticals, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Ionis Pharmaceuticals currently holds 1.45 B in liabilities with Debt to Equity (D/E) ratio of 2.01, implying the company greatly relies on financing operations through barrowing. Ionis Pharmaceuticals has a current ratio of 8.02, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Ionis Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Ionis Pharmaceuticals Total Assets Over Time

Ionis Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Ionis Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Ionis Pharmaceuticals Debt Ratio

    
  32.0   
It appears slightly above 68% of Ionis Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Ionis Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Ionis Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Ionis Pharmaceuticals Corporate Bonds Issued

Ionis Short Long Term Debt Total

Short Long Term Debt Total

1.53 Billion

At this time, Ionis Pharmaceuticals' Short and Long Term Debt Total is comparatively stable compared to the past year.

Understaning Ionis Pharmaceuticals Use of Financial Leverage

Ionis Pharmaceuticals' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Ionis Pharmaceuticals' current equity. If creditors own a majority of Ionis Pharmaceuticals' assets, the company is considered highly leveraged. Understanding the composition and structure of Ionis Pharmaceuticals' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last ReportedProjected for Next Year
Short and Long Term Debt Total1.5 B1.5 B
Net Debt1.1 B1.1 B
Short Term Debt53.2 M55.8 M
Long Term Debt1.2 B1.3 B
Long Term Debt Total1.4 B1.4 B
Short and Long Term Debt53.2 M43.5 M
Net Debt To EBITDA(4.58)(4.35)
Debt To Equity 4.65  6.35 
Interest Debt Per Share 12.55  13.17 
Debt To Assets 0.60  0.32 
Long Term Debt To Capitalization 0.82  0.42 
Total Debt To Capitalization 0.82  0.43 
Debt Equity Ratio 4.65  6.35 
Debt Ratio 0.60  0.32 
Cash Flow To Debt Ratio(0.17)(0.16)
Please read more on our technical analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.